# DynamX Bioadaptor Hong Kong Registry

> **NCT04483791** · PHASE4 · COMPLETED · sponsor: **Elixir Medical Corporation** · enrollment: 50 (actual)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **COMBINATION_PRODUCT:** DynamX Novolimus Eluting Coronary Bioadaptor System

## Key facts

- **NCT ID:** NCT04483791
- **Lead sponsor:** Elixir Medical Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-30
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2024-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04483791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04483791, "DynamX Bioadaptor Hong Kong Registry". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04483791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*